Even though the clinical relevance of your aforementioned cardiovascular hazard factor alterations by tirzepatide will probably be assessed from the prepared cardiovascular outcome research SURPASS-CVOT ( "kind":"clinical-demo","attrs": "textual content":"NCT04255433","term_id":"NCT04255433" NCT04255433), a pre-specified cardiovascular meta-Investi